Hypoglycemia in T2D patients has been shown to further exacerbate the condition through prothrombotic effects [16], enhanced platelet activation [17,18], inflammatory responses [19,20], altered endothelial microparticles [21] and cardiac arrhythmias [22] and to attenuate the vascular endothelial protective effect of glucagon-like peptide-1 (GLP-1) therapy [23]. This evidence concerns the gene GCG and chronic obstructive pulmonary disease.